Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10485434 | 0.85 | CRBN (0.31) | CRBN | |
| SCHEMBL10485439 | 0.85 | CRBN (0.31) | CRBN | |
| SCHEMBL633176 | 0.77 | MAPK1 (0.40) | CRBNCYP2C9CYP2C19LMNAALDH1A1 | |
| SCHEMBL10484761 | 0.76 | HPGD (0.32) | ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL10484751 | 0.76 | HPGD (0.32) | ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL10484629 | 0.76 | CRBN (0.35) | CRBNPDE7ACYP2C9CYP2C19LMNA | |
| SCHEMBL19628662 | 0.72 | ALDH1A1 (0.39) | CYP2C9CYP2C19LMNAALDH1A1HPGD | |
| SCHEMBL10485316 | 0.70 | CRBN (0.36) | CRBN | |
| SCHEMBL10485005 | 0.70 | LMNA (0.31) | CRBNLMNA | |
| SCHEMBL13687818 | 0.69 | CRBN (0.34) | CRBNPDE7ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-11-23 | — | — | US | disclosed |
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | CXXC5, ZRANB2, GZMB | CRBN 1749/4885PDE7A 2823/4885CYP2C9 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.